Effect of Severe Maternal Iron Deficiency Anemia on Neonatal Platelet Indices

The effect of iron deficiency anaemia treatment on mean platelet volume

AIM

To determine the relationship between mean platelet volume (MPV) and treatment response of iron deficiency anaemia (IDA) with normal platelet count. Study further aimed to determine changing of platelet parameters treatment response of IDA.

METHODS

IDA patients (n = 124) and the control group (CG) (n = 124) who fulfilled the inclusion criteria were compared for MPV and platelet parameters. Patients with IDA were divided into two groups as partial and complete response. The partial response to treatment group (PRG) was accepted as haemoglobin level between 10 and 12 g/dL, mean corpuscular volume (MCV) below 80 fL, and ferritin below 15 ng/ml (n = 60). Complete response to treatment group (CRG) was the patients whose haemoglobin was above 12 g/dL, MCV is above 80 fL, and ferritin is above 15 ng/ml (n = 64).

RESULTS

The MPV levels of CG (8.81 ± 0.99), PRG (8.80 ± 1.09), and CRG (8.96 ± 0.96) were similar at the beginning of the study. In addition, MPV levels of PRG (8.84 ± 1.08) and CRG (8.96 ± 1.11) with IDA therapy were similar at the end of the study (p > 0.05). When IDA was treated, there was a decrease in plateletcrit, platelet distribution width (PDW), and platelet count from platelet parameters. There was a correlation between MPV level and platelet count in both PRG and CRG (r = - 0.506; p < 0.001), (r = - 0.499; p < 0.001).

CONCLUSION

There is no change in MPV levels before and after treatment when normal platelet count IDA is treated, but there is a decrease in platelet count and an increase in PDW.

Hepcidin, Serum Iron, and Transferrin Saturation in Full-Term and Premature Infants during the First Month of Life: A State-of-the-Art Review of Existing Evidence in Humans

Neonates regulate iron at birth and in early postnatal life. We reviewed literature from PubMed and Ovid Medline containing data on umbilical cord and venous blood concentrations of hepcidin and iron, and transferrin saturation (TSAT), in human neonates from 0 to 1 mo of age. Data from 59 studies were used to create reference ranges for hepcidin, iron, and TSAT for full-term-birth (FTB) neonates over the first month of life. In FTB neonates, venous hepcidin increases 100% over the first month of life (to reach 61.1 ng/mL; 95% CI: 20.1, 102.0 ng/mL) compared with umbilical cord blood (29.7 ng/mL; 95% CI: 21.1, 38.3 ng/mL). Cord blood has a high concentration of serum iron (28.4 μmol/L; 95% CI: 26.0, 31.1 μmol/L) and levels of TSAT (51.7%; 95% CI: 46.5%, 56.9%). After a short-lived immediate postnatal hypoferremia, iron and TSAT rebounded to approximately half the levels in the cord by the end of the first month. There were insufficient data to formulate reference ranges for preterm neonates.